Moderna and MSD publicize promising study of cancer vaccine
Moderna’s personalized mRNA cancer vaccine in combination with cancer drug Keytruda from MSD has met a phase II study goal.
by marketwire, translated by daniel pedersen
Moderna, made a household name for its mRNA Covid-19 vaccine, is developing a personalized mRNA cancer vaccine for melanoma patients, and has just taken a further step in clinical development alongside pharmaceutical firm MSD.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab presents promising new data for cancer hope in US
For subscribers
